XSHE
300233
Market cap765mUSD
Oct 09, Last price
13.78CNY
1D
2.07%
1Q
4.00%
Jan 2017
-43.46%
IPO
36.23%
Name
Shandong Jincheng Pharmaceutical Group Co Ltd
Chart & performance
P/E
118.30
P/S
1.92
EPS
0.12
Div yield, %
2.96%
Shrs. gr., 5y
-0.33%
Rev. gr., 5y
-2.84%
Revenues
2.72b
-19.44%
Net income
44m
-77.55%
CFO
321m
+8.18%
Dividend
May 15, 20260.15 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shandong Jincheng Pharmaceutical Group Co., Ltd., together with its affiliated companies, focuses on the global research, development, manufacturing, and distribution of Cephalosporin intermediates. The Group's extensive product line includes active pharmaceutical ingredients (APIs), biopharmaceutical products, various medical intermediates, specialty fine chemicals, and final dosage form medications. Additionally, it diversifies its operations by offering animal nutrition and healthcare products, as well as providing contract manufacturing (CMO) and contract development and manufacturing (CDMO) services. Established in 2004, the company is headquartered in Zibo, China.
Key people
Jiaquan Li
Chairman of the Board, President · since 2025
Jing Liu
Chief Financial Officer · since 2023
Gengxiu Zheng
Chief Scientific Officer · since 2024
Xili Cui
Vice President · since 2023
Hui Wang
Vice President, Director · since 2024
Xicheng Zhang
Vice President · since 2024
Zhongzheng Zhang
Vice President, Director · since 2024
Xinzhe Yang
Vice President, Secretary of the Board · since 2025
Qinyuan Ma
Director · since 2023
Qixiao Cai
Independent Director · since 2020
Fuli Li
Independent Director · since 2023
Xinyu Wang
Independent Director · since 2020
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||